Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07211997 · ClinicalTrials.gov registry record

FebriDx® Pediatric Validation Study

A clinical trial of Acute Respiratory Infections (ARIs), sponsored by Lumos Diagnostics.

Recruiting
Registry status
800
Enrollment target
10
Study locations

NCT07211997: Recruiting study of Acute Respiratory Infections (ARIs), sponsored by Lumos Diagnostics.

NCT07211997 is a study of Acute Respiratory Infections (ARIs) that is actively recruiting participants, run by Lumos Diagnostics. The registered enrollment target is 800 participants, above the 97-participant average among 3 other Acute Respiratory Infections (ARIs) trials with a reported enrollment target (725% higher). The trial reports 10 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07211997, a study of Acute Respiratory Infections (ARIs), is actively recruiting participants, sponsored by Lumos Diagnostics.

RECRUITING
Registry status
800 participants
Enrollment target
10
Study locations

Study Summary

The primary objective of this study is to determine performance characteristics of the FebriDx® test in differentiating bacterial from non-bacterial etiology among febrile pediatric patients (2-11 years) presenting to the emergency department, urgent care center or primary care office with a suspected acute respiratory tract infection.

Primary Outcome

Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA) of the FebriDx results in determining the presence of a bacterial associated systemic host immune response compared to the reference standard of clinical adjudication as determined by a panel of pediatric experts using the Clinical Reference Algorithm.

Interventions

  • DEVICE FebriDx

Study Locations (10)

Florida

  • PAS Research- Myrtle Avenue Pediatrics, Inc - Clearwater
  • PAS Research- Sandhill Pediatrics PA - Lutz
  • PAS Research - Tampa

Ohio

  • Hometown Urgent Care - Huber Heights
  • Hometown Urgent Care - Springfield

South Carolina

  • Tribe - Charleston
  • Tribe- Parkside Pediatrics - Greenville

California

  • Avacare - Colton

Pennsylvania

  • PAS Research - Pittsburgh

Texas

  • PAS Research - Edinburg

Trial Details

FieldValue
Enrollment Target 800 participants
Start Date 2025-10-09
Est. Completion 2026-11-30
Lumos Diagnostics

6 total trials

What NCT07211997 shows while recruiting

NCT07211997 is an observational study that tracks outcomes without assigning an intervention. The registered 800 participants enrollment target is mid-sized for trials with a published cap, above the 97-participant average among 3 other Acute Respiratory Infections (ARIs) trials with a reported enrollment target (725% higher).

The record links to 1 condition, with Acute Respiratory Infections (ARIs) appearing as the primary indexed condition, and to 1 intervention - of which FebriDx is the first listed.

NCT07211997 lists 10 locations in 6 states (Florida, Ohio, South Carolina).

Frequently Asked Questions

What is clinical trial NCT07211997 about?

NCT07211997 is a clinical study titled "FebriDx® Pediatric Validation Study". The primary objective of this study is to determine performance characteristics of the FebriDx® test in differentiating bacterial from non-bacterial etiology among febrile pediatric patients (2-11 years) presenting to the emergency department, urgent care center or primary care office with a suspect...

What is the current status of trial NCT07211997?

This trial is currently recruiting. The enrollment target is 800 participants. The study started on 2025-10-09. Estimated completion is 2026-11-30.

What conditions does trial NCT07211997 study?

This clinical trial studies the following conditions: Acute Respiratory Infections (ARIs).

What interventions are being tested in trial NCT07211997?

The interventions under investigation include: FebriDx (DEVICE).

Who is sponsoring clinical trial NCT07211997?

This trial is sponsored by Lumos Diagnostics, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07211997 being conducted?

This trial has 10 study locations across California, Florida, Ohio, Pennsylvania, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acute Respiratory Infections (ARIs)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00695214 · 800 participants · Phase 2

    Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea

  • NCT03048201 · 800 participants · NA

    Physica System Total Knee Replacement Registry Study

  • NCT03792659 · 800 participants

    The EXPLORE MG Registry for Myasthenia Gravis

  • NCT03819296 · 800 participants · Phase 1

    Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07211997, the US trial registry maintained by the National Library of Medicine. NCT07211997 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.